Genetics of vascular malformations

Seminars in Pediatric Surgery

Volumn 23, Issue 4, 2014, Pages 221-226

  Nguyen, Ha Long ^a   Boon, Laurence M ^b   Vikkula, Miikka ^a  

^a DE DUVE INSTITUTE   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Familial; Genetics of vascular malformations; Somatic mosaicism; Sporadic

Indexed keywords

DNA; RNA;

ARTERIOVENOUS MALFORMATION; ARTICLE; CAPILLARY; CAPILLARY MALFORMATION; CLINICAL GENETICS; CONGENITAL BLOOD VESSEL MALFORMATION; GENE IDENTIFICATION; HIGH THROUGHPUT SCREENING; HUMAN; LYMPHATIC MALFORMATION; NONHUMAN; PRIORITY JOURNAL; VEIN MALFORMATION; GENETICS;

HUMANS; VASCULAR MALFORMATIONS;

EID: 84925942830     PISSN: 10558586     EISSN: 15329453     Source Type: Journal    
DOI: 10.1053/j.sempedsurg.2014.06.014     Document Type: Article

References (84)

1. Boon L.M., Ballieux F., Vikkula M. Pathogenesis of vascular anomalies. Clin Plast Surg 2011, 38(1):7-19.
2. Limaye N., et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet 2009, 41(1):118-124.
3. Limaye N., Boon L.M., Vikkula M. From germline towards somatic mutations in the pathophysiology of vascular anomalies. Hum Mol Genet 2009, 18(R1):R65-R74.
4. McAllister K.A., et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994, 8(4):345-351.
5. Johnson D.W., et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996, 13(2):189-195.
6. Shovlin C.L. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010, 24(6):203-219.
7. Srinivasan S., et al. A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet 2003, 12(5):473-482.
8. Torsney E., et al. Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality. Circulation 2003, 107(12):1653-1657.
9. Park S.O., et al. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest 2009, 119(11):3487-3496.
10. Gallione C.J., et al. SMAD4 mutations found in unselected HHT patients. J Med Genet 2006, 43(10):793-797.
11. Wooderchak-Donahue W.L., et al. BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. Am J Hum Genet 2013, 93(3):530-537.
12. Bayrak-Toydemir P., et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A 2006, 140(20):2155-2162.
13. Cole S.G., et al. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005, 42(7):577-582.
14. Boon L.M., Mulliken J.B., Vikkula M. RASA1: variable phenotype with capillary and arteriovenous malformations. Curr Opin Genet Dev 2005, 15(3):265-269.
15. Eerola I., et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 2003, 73(6):1240-1249.
16. Revencu N., et al. RASA1 mutations and associated phenotypes in 68 families with capillary malformation-arteriovenous malformation. Hum Mutat 2013, 34(12):1632-1641.
17. Revencu N., et al. Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations. Hum Mutat 2008, 29(7):959-965.
18. Kulkarni S.V., et al. Role of p120 Ras-GAP in directed cell movement. J Cell Biol 2000, 149(2):457-470.
19. Shirley M.D., et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med 2013, 368(21):1971-1979.
20. Revencu N., Vikkula M. Cerebral cavernous malformation: new molecular and clinical insights. J Med Genet 2006, 43(9):716-721.
21. Pagenstecher A., et al. A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum Mol Genet 2009, 18(5):911-918.
22. Akers A.L., et al. Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. Hum Mol Genet 2009, 18(5):919-930.
23. Zawistowski J.S., et al. CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis. Hum Mol Genet 2005, 14(17):2521-2531.
24. Voss K., et al. CCM3 interacts with CCM2 indicating common pathogenesis for cerebral cavernous malformations. Neurogenetics 2007, 8(4):249-256.
25. Wustehube J., et al. Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling. Proc Natl Acad Sci U S A 2010, 107(28):12640-12645.
26. Uhlik M.T., et al. Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock. Nat Cell Biol 2003, 5(12):1104-1110.
27. Chen L., et al. Apoptotic functions of PDCD10/CCM3, the gene mutated in cerebral cavernous malformation 3. Stroke 2009, 40(4):1474-1481.
28. You C., et al. Loss of CCM3 impairs DLL4-Notch signalling: implication in endothelial angiogenesis and in inherited cerebral cavernous malformations. J Cell Mol Med 2013, 17(3):407-418.
29. Amyere M., et al. Somatic uniparental isodisomy explains multifocality of glomuvenous malformations. Am J Hum Genet 2013, 92(2):188-196.
30. Brouillard P., Limaye N., Boon L.M., Vikkula M. Disorders of the venous system. Emery and Rimoin's Principles and Practice in Medical Genetics 2013, 1-9. Elsevier Science, [chapter 56]. D.L. Rimoin, R.E. Pyeritz, B.R. Korf (Eds.).
31. Wouters V., et al. Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects. Eur J Hum Genet 2010, 18(4):414-420.
32. Vikkula M., et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996, 87(7):1181-1190.
33. Soblet J., et al. Variable somatic TIE2 mutations in half of sporadic venous malformations. Mol Syndromol 2013, 4(4):179-183.
34. Uebelhoer M., et al. Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB. Hum Mol Genet 2013, 22(17):3438-3448.
35. Boon L.M., et al. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch Dermatol 2004, 140(8):971-976.
36. Brouillard P., et al. Four common glomulin mutations cause two thirds of glomuvenous malformations ("familial glomangiomas"): evidence for a founder effect. J Med Genet 2005, 42(2):e13.
37. Brouillard P., et al. Genotypes and phenotypes of 162 families with a glomulin mutation. Mol Syndromol 2013, 4(4):157-164.
38. Brouillard P., et al. Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations ("glomangiomas"). Am J Hum Genet 2002, 70(4):866-874.
39. McIntyre B.A., et al. Glomulin is predominantly expressed in vascular smooth muscle cells in the embryonic and adult mouse. Gene Expr Patterns 2004, 4(3):351-358.
40. Grisendi S., et al. Ligand-regulated binding of FAP68 to the hepatocyte growth factor receptor. J Biol Chem 2001, 276(49):46632-46638.
41. Chambraud B., et al. FAP48, a new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12. Prevention by the immunosuppressant drugs FK506 and rapamycin. J Biol Chem 1996, 271(51):32923-32929.
42. Tron A.E., et al. The glomuvenous malformation protein glomulin binds Rbx1 and regulates cullin RING ligase-mediated turnover of Fbw7. Mol Cell 2012, 46(1):67-78.
43. Brouillard P., Boon L., Vikkula M. Genetics of lymphatic anomalies. J Clin Invest 2014, 124(3):898-904.
44. Mendola A., et al. Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema. Mol Syndromol 2013, 4(6):257-266.
45. Karkkainen M.J., et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 2000, 25(2):153-159.
46. Irrthum A., et al. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet 2000, 67(2):295-301.
47. Ghalamkarpour A., et al. Recessive primary congenital lymphoedema caused by a VEGFR3 mutation. J Med Genet 2009, 46(6):399-404.
48. Dumont D.J., et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998, 282(5390):946-949.
49. Gordon K., et al. FLT4/VEGFR3 and Milroy disease: novel mutations, a review of published variants and database update. Hum Mutat 2013, 34(1):23-31.
50. Dellinger M.T., et al. Chy-3 mice are Vegfc haploinsufficient and exhibit defective dermal superficial to deep lymphatic transition and dermal lymphatic hypoplasia. Dev Dyn 2007, 236(8):2346-2355.
51. Au A.C., et al. Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function and choanal development in humans. Am J Hum Genet 2010, 87(3):436-444.
52. Fang J., et al. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet 2000, 67(6):1382-1388.
53. Finegold D.N., et al. Truncating mutations in FOXC2 cause multiple lymphedema syndromes. Hum Mol Genet 2001, 10(11):1185-1189.
54. Kume T. Foxc2 transcription factor: a newly described regulator of angiogenesis. Trends Cardiovasc Med 2008, 18(6):224-228.
55. Kriederman B.M., et al. FOXC2 haploinsufficient mice are a model for human autosomal dominant lymphedema-distichiasis syndrome. Hum Mol Genet 2003, 12(10):1179-1185.
56. Irrthum A., et al. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am J Hum Genet 2003, 72(6):1470-1478.
57. Moalem S., et al. Hypotrichosis-lymphedema-telangiectasia-renal defect associated with a truncating mutation in the SOX18 gene. Clin Genet 2014, doi:10.1111/cge.12388.
58. Pennisi D., et al. Mutations in Sox18 underlie cardiovascular and hair follicle defects in ragged mice. Nat Genet 2000, 24(4):434-437.
59. Jeltsch M., et al. CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation. Circulation 2014, 129(19):1962-1971.
60. Alders M., et al. Evaluation of clinical manifestations in patients with severe lymphedema with and without CCBE1 mutations. Mol Syndromol 2013, 4(3):107-113.
61. Hogan B.M., et al. Ccbe1 is required for embryonic lymphangiogenesis and venous sprouting. Nat Genet 2009, 41(4):396-398.
62. Ostergaard P., et al. Mutations in KIF11 cause autosomal-dominant microcephaly variably associated with congenital lymphedema and chorioretinopathy. Am J Hum Genet 2012, 90(2):356-362.
63. Chauviere M., Kress C., Kress M. Disruption of the mitotic kinesin Eg5 gene (Knsl1) results in early embryonic lethality. Biochem Biophys Res Commun 2008, 372(4):513-519.
64. Roberts C.M., et al. A novel NEMO gene mutation causing osteopetrosis, lymphoedema, hypohidrotic ectodermal dysplasia and immunodeficiency (OL-HED-ID). Eur J Pediatr 2010, 169(11):1403-1407.
65. Flister M.J., et al. Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. Blood 2010, 115(2):418-429.
66. Kanady J.D., Simon A.M. Lymphatic communication: connexin junction, what[U+05F3]s your function?. Lymphology 2011, 44(3):95-102.
67. Ferrell R.E., et al. GJC2 missense mutations cause human lymphedema. Am J Hum Genet 2010, 86(6):943-948.
68. Odermatt B., et al. Connexin 47 (Cx47)-deficient mice with enhanced green fluorescent protein reporter gene reveal predominant oligodendrocytic expression of Cx47 and display vacuolized myelin in the CNS. J Neurosci 2003, 23(11):4549-4559.
69. Li X., et al. Ablation of Cx47 in transgenic mice leads to the loss of MUPP1, ZONAB and multiple connexins at oligodendrocyte-astrocyte gap junctions. Eur J Neurosci 2008, 28(8):1503-1517.
70. Brice G., et al. A novel mutation in GJA1 causing oculodentodigital syndrome and primary lymphoedema in a three generation family. Clin Genet 2013, 84(4):378-381.
71. Kazenwadel J., et al. Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. Blood 2012, 119(5):1283-1291.
72. Ostergaard P., et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 2011, 43(10):929-931.
73. Zhou Y., et al. Rescue of the embryonic lethal hematopoietic defect reveals a critical role for GATA-2 in urogenital development. EMBO J 1998, 17(22):6689-6700.
74. Fujiwara Y., et al. Functional overlap of GATA-1 and GATA-2 in primitive hematopoietic development. Blood 2004, 103(2):583-585.
75. Kurek K.C., et al. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet 2012, 90(6):1108-1115.
76. Lindhurst M.J., et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 2011, 365(7):611-619.
77. Kurek K.C., et al. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Gen 2012, 90(6):1108-1115.
78. Hu F.Y., et al. AGGF1 is a novel anti-inflammatory factor associated with TNF-alpha-induced endothelial activation. Cell Signal 2013, 25(8):1645-1653.
79. Chen D., et al. Functional characterization of Klippel-Trenaunay syndrome gene AGGF1 identifies a novel angiogenic signaling pathway for specification of vein differentiation and angiogenesis during embryogenesis. Hum Mol Genet 2013, 22(5):963-976.
80. Lindhurst M.J., et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 2011, 365(7):611-619.
81. Mester J.L., et al. Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model. Eur J Hum Genet 2011, 19(7):763-768.
82. Fukai A., et al. Akt1 in murine chondrocytes controls cartilage calcification during endochondral ossification under physiologic and pathologic conditions. Arthritis Rheum 2010, 62(3):826-836.
83. Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003, 22(3):183-198.
84. Mester J., Eng C. When overgrowth bumps into cancer: the PTEN-opathies. Am J Med Genet C Semin Med Genet 2013, 163C(2):114-121.